The Somewhat Positive Media Coverage Extremely Likely to Affect bluebird bio (BLUE) Stock Price

The Somewhat Positive Media Coverage Extremely Likely to Affect bluebird bio (BLUE) Stock Price

These are some of the headlines that may have effected AlphaOne’s scoring:

Media coverage about bluebird bio (NASDAQ:BLUE) has trended somewhat positive on Monday, according to Alpha One Sentiment Analysis. The research firm, a service of Accern, scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. bluebird bio earned a news sentiment score of 0.25 on Alpha One’s scale. Alpha One also gave news headlines about the biotechnology company an impact score of 98 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the near future.

A number of analysts have recently issued reports on BLUE shares. BTIG Research reissued a “buy” rating on shares of bluebird bio in a research note on Monday, May 1st. Jefferies Group LLC reissued a “buy” rating and set a $88.00 target price on shares of bluebird bio in a research note on Friday, March 24th. Zacks Investment Research lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Tuesday, April 25th. Morgan Stanley upped their price objective on shares of bluebird bio from $87.00 to $91.00 and gave the stock an “equal weight” rating in a research note on Monday, May 8th. Finally, Roth Capital set a $71.00 price objective on shares of bluebird bio and gave the stock a “hold” rating in a research note on Thursday, February 23rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $88.59. bluebird bio (NASDAQ:BLUE) opened at 84.15 on Monday. bluebird bio has a one year low of $36.62 and a one year high of $100.40. The firm’s market cap is $3.45 billion. The company has a 50-day moving average of $85.35 and a 200 day moving average of $77.88.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.76) by $0.08. The company had revenue of $6.83 million for the quarter, compared to the consensus estimate of $1.51 million. bluebird bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. Equities research analysts expect that bluebird bio will post ($6.82) earnings per share for the current fiscal year. In other news, Director Daniel Lynch sold 3,000 shares of the stock in a transaction that occurred on Monday, March 27th. The stock was sold at an average price of $88.12, for a total transaction of $264,360.00. Following the sale, the director now directly owns 3,400 shares in the company, valued at approximately $299,608. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jason Cole sold 4,930 shares of the stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $100.07, for a total value of $493,345.10. Following the sale, the insider now owns 16,981 shares in the company, valued at $1,699,288.67. The disclosure for this sale can be found here. Insiders have sold a total of 17,417 shares of company stock worth $1,586,827 over the last quarter. Insiders own 3.50% of the company’s stock.

About bluebird bio bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:BLUE”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for bluebird bio Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for bluebird bio Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment